Recombinant human papillomavirus nonavalent vaccine in the prevention of cancers caused by human papillomavirus
ZQ Toh, J Kosasih, FM Russell… - Infection and drug …, 2019 - Taylor & Francis
Human papillomavirus (HPV) types 16 and 18 cause 70% of cervical cancer cases globally.
The nonavalent HPV vaccine (9vHPV) was licensed in 2014 and protects against the next …
The nonavalent HPV vaccine (9vHPV) was licensed in 2014 and protects against the next …
Proof-of-principle evaluation of the efficacy of fewer than three doses of a bivalent HPV16/18 vaccine
AR Kreimer, AC Rodriguez… - Journal of the …, 2011 - academic.oup.com
Background Three-dose regimens for human papillomavirus (HPV) vaccines are expensive
and difficult to complete, especially in settings where the need for cervical cancer prevention …
and difficult to complete, especially in settings where the need for cervical cancer prevention …
Recent developments in human papillomavirus (HPV) vaccinology
AL Williamson - Viruses, 2023 - mdpi.com
Human papillomavirus (HPV) is causally associated with 5% of cancers, including cancers
of the cervix, penis, vulva, vagina, anus and oropharynx. The most carcinogenic HPV is HPV …
of the cervix, penis, vulva, vagina, anus and oropharynx. The most carcinogenic HPV is HPV …
Efficacy of human papillomavirus vaccines: a systematic quantitative review
LR Medeiros, DD Rosa, MI Da Rosa… - International Journal of …, 2009 - ijgc.bmj.com
Human papillomavirus (HPV) types cause approximately 70% of cervical cancer worldwide.
Two vaccines have been recently evaluated in randomized controlled trials: the bivalent …
Two vaccines have been recently evaluated in randomized controlled trials: the bivalent …
Immunogenicity and safety of the human papillomavirus 6, 11, 16, 18 vaccine in HIV-infected young women
JA Kahn, J Xu, BG Kapogiannis, B Rudy… - Clinical infectious …, 2013 - academic.oup.com
Background The objective of this study was to determine whether the 3-dose quadrivalent
human papillomavirus (HPV) vaccine series (HPV-6,-11,-16,-18) is immunogenic and safe in …
human papillomavirus (HPV) vaccine series (HPV-6,-11,-16,-18) is immunogenic and safe in …
Efficacy of a quadrivalent prophylactic human papillomavirus (types 6, 11, 16, and 18) L1 virus-like-particle vaccine against high-grade vulval and vaginal lesions: a …
EA Joura, S Leodolter, M Hernandez-Avila… - The Lancet, 2007 - thelancet.com
Background Vulval and vaginal cancers among younger women are often related to
infection with human papillomavirus (HPV). These cancers are preceded by high-grade …
infection with human papillomavirus (HPV). These cancers are preceded by high-grade …
Current findings from prophylactic HPV vaccine trials
LA Koutsky, DM Harper - Vaccine, 2006 - Elsevier
Early data from randomized controlled trials consistently show that prophylactic human
papillomavirus virus-like particle (HPV VLP) vaccines are effective in preventing infection …
papillomavirus virus-like particle (HPV VLP) vaccines are effective in preventing infection …
Human papillomavirus 9-valent vaccine for cancer prevention: a systematic review of the available evidence
C Signorelli, A Odone, V Ciorba, P Cella… - Epidemiology & …, 2017 - cambridge.org
In 2014, the Food and Drug Administration approved a new human papillomavirus 9-valent
vaccine (9vHPV), targeting nine HPV types: HPV types 6, 11, 16, and 18, which are also …
vaccine (9vHPV), targeting nine HPV types: HPV types 6, 11, 16, and 18, which are also …
Evaluation of durability of a single dose of the bivalent HPV vaccine: the CVT trial
AR Kreimer, JN Sampson, C Porras… - JNCI: Journal of the …, 2020 - academic.oup.com
Background The authors investigated the durability of vaccine efficacy (VE) against human
papillomavirus (HPV) 16 or 18 infections and antibody response among nonrandomly …
papillomavirus (HPV) 16 or 18 infections and antibody response among nonrandomly …
The impact of quadrivalent human papillomavirus (HPV; types 6, 11, 16, and 18) L1 virus-like particle vaccine on infection and disease due to oncogenic nonvaccine …
DR Brown, SK Kjaer, K Sigurdsson… - The Journal of …, 2009 - academic.oup.com
Abstract Background Human papillomavirus (HPV)–6/11/16/18 vaccine reduces the risk of
HPV-6/11/16/18–related cervical intraepithelial neoplasia (CIN) 1–3 or adenocarcinoma in …
HPV-6/11/16/18–related cervical intraepithelial neoplasia (CIN) 1–3 or adenocarcinoma in …